Patent classifications
A01N43/00
Purinone derivative
Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
Coating of clay micro-tubes on surfaces of hair and natural fibers
A hair coloring mixture including a carrier liquid with alumino-silicate micro-tubes having a hair dye agent loaded into the lumen of the micro-tubes. The micro-tubes may be present in the carrier liquid in a concentration of between about 5 mg/ml and about 50 mg/ml, while the mixture will have a pH of between about 4 and about 7.
Compounds for treating spinal muscular atrophy
- Matthew G. Woll ,
- Guangming Chen ,
- Soongyu Choi ,
- Amal Dakka ,
- Song Huang ,
- Gary Mitchell Karp ,
- Chang-Sun Lee ,
- Chunshi Li ,
- Jana Narasimhan ,
- Nikolai Naryshkin ,
- Sergey Paushkin ,
- Hongyan Qi ,
- Anthony A. Turpoff ,
- Marla L. Weetall ,
- Ellen Welch ,
- Tianle Yang ,
- Nanjing Zhang ,
- Xiaoyan Zhang ,
- Xin Zhao ,
- Emmanuel Pinard ,
- Hasane Ratni
Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy. In a specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN2 into mRNA that is transcribed from the SMN2 gene. In another specific embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 into mRNA that is transcribed from the SMN1 gene. In yet another embodiment, provided herein are compounds of a form that may be used to modulate the inclusion of exon 7 of SMN1 and SMN2 into mRNA that is transcribed from the SMN1 and SMN2 genes, respectively.
SILVER- AND COPPER-CHELATING IONIC LIQUIDS, POLYMERS, AND GELS, AND USES THEREOF
Disclosed are methods of antimicrobial treatment using ionic liquids (ILs), IL complexes, polymers comprising ILs, and polymers comprising neutral ethylene diamine compounds. Also disclosed are novel IL complexes, polymers comprising ILs, and polymers comprising neutral ethylene diamine compounds.
Compositions and methods of product application to target and kill all life stages of bed bugs
The present disclosure generally relates to the field of pest elimination including all life stages of bed bugs. The present disclosure includes compositions and methods of product application to target and kill all life stages of bed bugs.
Ionic liquids for transdermal drug delivery
The compositions and methods described herein are topically applied to the skin with negligible or no skin irritation and can direct or prevent transport through the skin. The compositions contain neat ionic liquids, optionally in combination with a drug to be delivered. In a preferred embodiment, the compositions increase transdermal transport of the drug to be delivered. In some embodiments, the compositions disrupt bacterial biofilms. This is particularly beneficial in the treatment of antibiotic resistant skin infections. In other embodiments, the compositions direct delivery within the skin. In still other embodiments, the compositions prevent transfer of substances through the stratum corneum. The disclosed compositions and methods can be tuned and modified such that they can be used to treat or prevent a variety of different diseases and disorders.
Isolated Bacterial Strain of the Genus Burkholderia and Pesticidal Metabolites Therefrom
A species of Burkholderia sp with no known pathogenicity to vertebrates but with pesticidal activity (e.g., plants, insects, fungi, weeds and nematodes) is provided. Also provided are natural products derived from a culture of said species and methods of controlling pests using said natural products.
Tricyclic compounds as inhibitors of mutant IDH enzymes
- Christian Fischer ,
- Stephane L. Bogen ,
- Matthew L. Childers ,
- Francesc Xavier Fradera Llinas ,
- J. Michael Ellis ,
- Sara Esposite ,
- Qingmei Hong ,
- Chunhui Huang ,
- Alexander J. Kim ,
- John W. Lampe ,
- Michelle R. Machacek ,
- Daniel R. McMasters ,
- Ryan D. Otte ,
- Dann L. Parker, Jr. ,
- Michael Reutershan ,
- Nunzio Sciammetta ,
- Pengcheng P. Shao ,
- David L. Sloman ,
- Feroze Ujjainwalla ,
- Catherine White ,
- Zhicai Wu ,
- Yang Yu ,
- Kake Zhao ,
- Craig Gibeau ,
- Tesfaye Biftu ,
- Purakkattle Biju ,
- Lei Chen ,
- Joshua Close ,
- Peter H. Fuller ,
- Xianhai Huang ,
- Min K. Park ,
- Valdimir Simov ,
- David J. Witter ,
- Hongjun Zhang
The present invention is directed to tricyclic compounds of formula (I) which are inhibitors of one or more mutant IDH enzymes: (I). The present invention is also directed to uses of the tricyclic compounds described herein in the potential treatment or prevention of cancers in which one or more mutant IDH enzymes are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such cancers. ##STR00001##
Substituted anilines as CCR(4) antagonists
Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
Heteroaryl compounds as IRAK inhibitors and uses thereof
The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as IRAK inhibitors.